Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.23.1
Significant Transactions (Narrative) (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 19, 2022
USD ($)
shares
Sep. 16, 2022
USD ($)
Nov. 01, 2021
USD ($)
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2023
USD ($)
item
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
General and administrative expenses         $ 3,525,000 $ 5,316,000 $ 16,407,000 $ 14,863,000  
Value of common stock issued         16,000   16,000   $ 9,000
Secured Term Loan                  
Secured term loan     $ 22,375,000   13,852,000   13,852,000   22,375,000
Interest rate (as percent)     3.25%            
Cost incurred to attain debt         $ 152,000   152,000   214,000
RubrYc Therapeutics, Inc. [Member]                  
Estimated fair value   $ 650,000,000              
Milestone payments $ 5,000,000                
Amount advanced   484,000,000              
Transaction costs   208,000,000              
Finance leases     $ 813,822            
Number of shares issued | shares 102,354                
Value of common stock issued $ 1,000,000                
College Station Investors LLC And Bryan Capital [Member]                  
Total purchase price     28,750,000            
Cash payment     28,000,000            
Fair market value of property     $ 151,450            
Percentage of base rent     6.50%            
Cash consideration for equity interest acquired     $ 50,000            
Number of warrants issued | shares     51,583            
Warrants, exercise price per share | $ / shares     $ 33.25            
Shares issued under the Warrant | shares     11,583            
Fair value of the warrant     $ 217,255            
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan                  
Secured term loan     $ 22,375,000            
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock                  
Warrants issuable | shares     1            
Percentage of equity interest     0.01%            
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]                  
Collaboration and license agreement, agreement term       5 years          
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics, Inc. [Member]                  
Collaboration and license agreement, royalty payment term       10 years          
Stock Purchase Agreement [Member] | RubrYc Therapeutics, Inc. [Member]                  
Finance leases   $ 814,000              
Separation Agreement and General Release [Member]                  
General and administrative expenses             $ 2,130,000    
Period of bi-monthly installments of current base salary             24 months    
Period of bi-monthly installments of target bonus             24 months    
Maximum period for coverage of health insurance             18 months    
COBRA subsidy period             18 months    
Number of times on which lump sum cash payment tis o be made | item             6    
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]                  
Stock purchase agreement, number of shares purchased | shares       2,864,345          
Stock purchase agreement, value of shares purchased       $ 7,500,000          
Impairment of investment in equity security                 1,760,000
Impairment of current prepaid expense                 288,000
Impairment of non-current prepaid expense                 $ 864,000